191 related articles for article (PubMed ID: 28712967)
21. Quality of parental bonding is associated with symptom severity and functioning among individuals at ultra-high risk for psychosis.
Peh OH; Rapisarda A; Lee J
Schizophr Res; 2020 Jan; 215():204-210. PubMed ID: 31699626
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic validity of assessment scales for depression in patients with schizophrenia.
Kim SW; Kim SJ; Yoon BH; Kim JM; Shin IS; Hwang MY; Yoon JS
Psychiatry Res; 2006 Sep; 144(1):57-63. PubMed ID: 16904189
[TBL] [Abstract][Full Text] [Related]
23. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS).
Lançon C; Auquier P; Reine G; Bernard D; Toumi M
J Affect Disord; 2000 May; 58(2):107-15. PubMed ID: 10781700
[TBL] [Abstract][Full Text] [Related]
24. Assessing negative symptoms in schizophrenia: Validity of the clinical assessment interview for negative symptoms in Singapore.
Rekhi G; Ang MS; Yuen CKY; Ng WY; Lee J
Schizophr Res; 2019 Apr; 206():177-182. PubMed ID: 30558979
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic validity of the Eppendorf Schizophrenia Inventory (ESI): a self-report screen for ultrahigh risk and acute psychosis.
Niessen MA; Dingemans PM; van de Fliert R; Becker HE; Nieman DH; Linszen D
Psychol Assess; 2010 Dec; 22(4):935-44. PubMed ID: 21133552
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal patterns of social functioning and conversion to psychosis in subjects at ultra-high risk.
Jang JH; Shin NY; Shim G; Park HY; Kim E; Jang GE; Kwon SJ; Hur JW; An SK; Kwon JS
Aust N Z J Psychiatry; 2011 Sep; 45(9):763-70. PubMed ID: 21827349
[TBL] [Abstract][Full Text] [Related]
27. [Validation of the French version of the self-evaluation of negative symptoms (SNS)].
Hervochon C; Bourgeois V; Rotharmel M; Duboc JB; Le Goff B; Quesada P; Campion D; Dollfus S; Guillin O
Encephale; 2018 Dec; 44(6):512-516. PubMed ID: 29195803
[TBL] [Abstract][Full Text] [Related]
28. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
Addington D; Addington J; Atkinson M
Schizophr Res; 1996 May; 19(2-3):205-12. PubMed ID: 8789919
[TBL] [Abstract][Full Text] [Related]
29. The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G).
Müller MJ; Marx-Dannigkeit P; Schlösser R; Wetzel H; Addington D; Benkert O
J Psychiatr Res; 1999; 33(5):433-43. PubMed ID: 10504012
[TBL] [Abstract][Full Text] [Related]
30. Personality features in ultra-high risk for psychosis: a comparative study with schizophrenia and control subjects using the Temperament and Character Inventory-Revised (TCI-R).
Fresán A; León-Ortiz P; Robles-García R; Azcárraga M; Guizar D; Reyes-Madrigal F; Tovilla-Zárate CA; de la Fuente-Sandoval C
J Psychiatr Res; 2015 Feb; 61():168-73. PubMed ID: 25554622
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of the psychometric properties of the Calgary Depression Scale for Schizophrenics (CDSS) in a Hungarian clinical population of patients with schizophrenia].
Nagy J; Bitter I
Neuropsychopharmacol Hung; 2011 Mar; 13(1):33-40. PubMed ID: 21451190
[TBL] [Abstract][Full Text] [Related]
32. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia.
Lako IM; Bruggeman R; Knegtering H; Wiersma D; Schoevers RA; Slooff CJ; Taxis K
J Affect Disord; 2012 Sep; 140(1):38-47. PubMed ID: 22099566
[TBL] [Abstract][Full Text] [Related]
34. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
Rekhi G; Alphs L; Ang MS; Lee J
Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
[TBL] [Abstract][Full Text] [Related]
36. Scales for evaluating depressive symptoms in Chinese patients with schizophrenia.
Liu H; Zhang H; Xiao W; Liu Q; Fu P; Chen J; Wang G; Yang F; Wang G; Wang X; Li L
J Nerv Ment Dis; 2009 Feb; 197(2):140-2. PubMed ID: 19214051
[TBL] [Abstract][Full Text] [Related]
37. What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?
Schennach R; Riedel M; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
Eur Psychiatry; 2015 Jan; 30(1):43-50. PubMed ID: 25541347
[TBL] [Abstract][Full Text] [Related]
38. Validation and optimal cut-off score of the World Health Organization Well-being Index (WHO-5) as a screening tool for depression among patients with schizophrenia.
Fekih-Romdhane F; Al Mouzakzak F; Abilmona G; Dahdouh O; Hallit S
BMC Psychiatry; 2024 May; 24(1):391. PubMed ID: 38783217
[TBL] [Abstract][Full Text] [Related]
39. Validation of the Arabic Version of Calgary Depression Scale for Schizophrenia.
Hani Y; Ghuloum S; Mahfoud Z; Opler M; Khan A; Yehya A; Abdulhakam A; Hammoudeh S; Al-Mujalli A; Elsherbiny R; Al-Amin H
PLoS One; 2016; 11(9):e0162304. PubMed ID: 27583831
[TBL] [Abstract][Full Text] [Related]
40. Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS.
Rabany L; Weiser M; Werbeloff N; Levkovitz Y
Schizophr Res; 2011 Mar; 126(1-3):226-30. PubMed ID: 21115328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
